Federal solicitation · BAA-23-100-SOL-00004 · back to recent
Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
- Agency
- HEALTH AND HUMAN SERVICES, DEPARTMENT OF
- Status
- Open
- Response deadline
- Not posted
- Posted
- September 25, 2026
- Set-aside
- Not listed
- NAICS
- Not listed
- Estimated value
- $213.9M (as posted)
- Source
- View on SAM.gov
- Last checked
- 2026-09-26
Data this profile does not cover
- No likely incumbent surfaced; the solicitation number did not match any award record in the trailing window.